Compounded Semaglutide

GLP-1 receptor agonist supporting insulin sensitivity and weight management.

Overview

Semaglutide is a GLP-1 receptor agonist. The compounded formulation is prepared by FDA-registered, state-licensed compounding pharmacies. It is not FDA-approved and has not undergone FDA premarket review for safety, efficacy, or quality. Brand-name semaglutide products (Ozempic, Wegovy) are FDA-approved; the compounded formulation is a distinct, non-approved product.

Mechanism

GLP-1 receptors are present in the pancreas, GI tract, and central nervous system. Activation modulates insulin secretion in a glucose-dependent manner, slows gastric emptying, and affects appetite signaling pathways. Research on brand-name formulations has documented cardiovascular and metabolic effects. Whether compounded formulations produce equivalent results has not been independently established.

Clinical Considerations

• Contraindicated: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
• Animal studies showed potential thyroid C-cell tumor risk. Human relevance not confirmed.
• Common: nausea, reduced appetite, GI symptoms during dose titration.
• Prescription required following provider evaluation.
• HSA/FSA eligible when prescribed for a qualifying medical condition.

Potential Side Effects

• Nausea — most common, particularly during dose titration. Typically decreases over 4–8 weeks.
• Vomiting, diarrhea, or constipation — GI effects are dose-dependent and usually improve.
• Reduced appetite — an expected pharmacological effect.
• Injection site reactions: redness, bruising, or itching at the injection site.
• Rare: pancreatitis. Seek immediate medical attention for severe, persistent abdominal pain.
• Rare: gallbladder disease — risk increases with rapid weight loss.
• Contraindicated in personal or family history of MTC or MEN2.

All prescriptions require a telehealth consultation with a licensed provider. A prescription is not guaranteed. Individual results vary. Not FDA-approved unless noted otherwise.